University of North Carolina, Chapel Hill

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).

1,109 total trials 108 currently recruiting 881 completed early-phase tilt top decile by trial count

University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.

University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.

Top-decile sponsor footprint

University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,109 total, page 10 of 23

COMPLETED NA

Triggered Escalating Real-time Adherence (TERA) Intervention

NCT03292432

COMPLETED NA

Neurobehavioral Plasticity to Regular Sugar-Sweetened Beverage Intake: An fMRI Experiment

NCT03490734

COMPLETED Phase 2

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

NCT03489629

COMPLETED Phase 2

Safety of Sildenafil in Premature Infants

NCT03142568

COMPLETED NA

Using the LENA System in Early Intervention - b

NCT03480841

COMPLETED Phase 2

Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease

NCT03301272

COMPLETED NA

ATN 151 Work-to-Prevent: Employment as HIV Prevention

NCT03313310

COMPLETED NA

Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis

NCT03301740

COMPLETED NA

Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders

NCT03388294

COMPLETED

Multimodal Analgesic Protocol to Moderate Acute Pain

NCT03456141

COMPLETED

Neurophysiology, Estrogen, and Stress Exposure in the Emergence of Depression in Adolescent Girls

NCT03450135

COMPLETED NA

Developing a Biomarker Panel to Assess Choline Nutritional Status

NCT03234062

TERMINATED Early Phase 1

Screening Inhaled Allergen Challenge for Dermatophagoides Farinae

NCT03049111

COMPLETED NA

Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk

NCT03372369

COMPLETED NA

One-session Treatment for Spider Fears

NCT03410264

COMPLETED NA

Analysis of Orthodontic Tooth Movement Using 3D Imaging

NCT03398798

COMPLETED Phase 1

Salvage Peanut Oral Immunotherapy Study

NCT03251508

COMPLETED Phase 1

Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects

NCT03395119

COMPLETED Phase 1

Systemic Inflammatory Response to CCRE

NCT02847247

COMPLETED NA

Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia

NCT03287778

COMPLETED NA

Active and Passive Music Therapy Interventions

NCT03362944

COMPLETED NA

Targeting Auditory Hallucinations With Alternating Current Stimulation

NCT03221270

COMPLETED NA

Sustaining Physical Activity Following Cardiac Rehabilitation Completion

NCT03991715

COMPLETED NA

Feasibility of High Intensity Interval Training in Knee Osteoarthritis

NCT03281668

COMPLETED Phase 2

Study of Nicotinamide in Early Onset Preeclampsia

NCT03419364

COMPLETED NA

The Sensorimotor Locus of Balance Control in Elderly Gait

NCT03341728

COMPLETED Phase 2

Age of Blood in Sickle Cell Transfusion

NCT03704922

COMPLETED NA

Learning to Love Mealtime Together

NCT04502979

COMPLETED NA

Improving Access to a Primary Care Based Positive Parenting Program

NCT03077321

COMPLETED Phase 3

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

NCT05405244

COMPLETED NA

The Effects of Auditory Cues on Gait Mechanics in Parkinson's Disease

NCT03253965

COMPLETED NA

The Acute Effects of an Isometric Loading Intervention on Lower Extremity Landing Biomechanics in Individuals With Patellar Tendinopathy

NCT03262181

COMPLETED NA

Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy

NCT03243084

COMPLETED NA

The S.M.A.R.T. Project: Stress Management and Resilience Training for Teens

NCT03270943

COMPLETED Phase 2

Buproprion for Binge Drinking

NCT03169244

COMPLETED NA

Effects of a Valgus Unloader Brace on Medial Femoral Cartilage

NCT03272672

COMPLETED

Nasal and Peripheral Blood Biomarkers of CRS Patients Before and After Surgical Intervention

NCT03250429

COMPLETED Phase 2

Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension

NCT03196076

COMPLETED

Binge-Eating Genetics Initiative (BEGIN) - Dynamical Systems Approach

NCT04162574

COMPLETED NA

Transcranial Static Magnetic Field Stimulation of Frontal Cortex

NCT03244501

TERMINATED NA

Investigation of Oscillations Underlying Human Cognitive and Affective Processing Using Intracranial EEG

NCT03268694

COMPLETED NA

Effect of tACS Stimulation on Alpha Oscillations

NCT03178344

COMPLETED

Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge

NCT03229928

COMPLETED NA

Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device

NCT03185650

TERMINATED NA

Prospective, Comparative Assessment of Alveolar Bone Augmentation Using GUIDOR® Membrane in the Bound Edentulous Space

NCT02387008

COMPLETED Phase 4

ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence

NCT03218592

COMPLETED Phase 1

Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)

NCT03212989

COMPLETED NA

Evaluation of Coronary Artery Calcification Using Gated Stationary Chest Tomosynthesis

NCT03169062

COMPLETED NA

Development of a Novel Transdiagnostic Intervention for Anhedonia - R61 Phase

NCT02874534

COMPLETED NA

Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study

NCT03076775

← Previous Page 10 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 111
Phase 2 92
Phase 3 13
Phase 4 56

What is open in the University of North Carolina, Chapel Hill pipeline

108 recruiting of 1,109 indexed (10% open); 881 completed (79%).

Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).

Top condition: Obesity (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of North Carolina, Chapel Hill: open-pipeline peers nationwide

Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of North Carolina, Chapel HillUniversity of FloridaWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthChildren's Hospitals and Clinics of MinnesotaCytokineticsSanofiOhio University
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,109 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this University of North Carolina, Chapel Hill page

1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.

  • 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.